A Phase 3 interventional study of IV Acetaminophen in Pain and Fever, sponsored by Mallinckrodt. Completed at 14 sites in United States. Open to participants aged 37 Weeks to 16 Years. Per ClinicalTrials.gov, last updated 2017-05-10.
Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.
Among the 137 studies testing acetaminophen in Pain, this one is the 63rd largest by enrollment, is one of 8 that started in 2008, is one of 22 in phase 3, and was the 21st registered.
10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.
Browse Pain studies →5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Horizon Health Network · Sites in Canada
Ages 19+
University of Gaziantep · Sites in Turkey
Ages 18–75
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Baskent University · Sites in Turkey
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 37 Weeks to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 25 · Phase 4 67
First in 2003; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 66 across 8,511 interventional studies indexed under Pain.
Median enrollment 95 across the 137 interventional studies. Of the 115 that completed or were terminated, 53 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 137 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mallinckrodt, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Mallinckrodt is the lead sponsor of 87 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 15 (100%) have results posted.
16 studies in Pain by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 16 studies in Pain by Keenova Therapeutics plc, this one is the 8th largest by enrollment, is one of 3 that started in 2008, is one of 11 in phase 3, and was the 6th registered.
Keenova Therapeutics plc’s Pain studies by the year they started, since 2001.
4 of the studies testing acetaminophen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07368738Horizon Health NetworkIntravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy | 2027-04 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07536425Western Galilee Hospital-NahariyaPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 137 studies testing acetaminophen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 16 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Intravenous acetaminophen (IVAPAP) is safe in repeated dose, multi-day clinical use when administered at a daily dose of 40 to 75 mg/kg body weight
To assess the safety of intravenous acetaminophen (IV APAP) when used over one or more days for the treatment of acute pain or fever in pediatric (neonates, infants, children and adolescents) inpatients who are unable to take anything by mouth (NPO), require or would benefit from IV treatment, or are willing and able to stay on IVAPAP therapy for 1 to 7 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 to 75 mg/kg/day every 4 to 6 hours
Drug: IV Acetaminophen
Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
Also known as: IV APAP, APAP
Number of Subjects Reporting at Least One Treatment Emergent Adverse Event (TEAE)
A TEAE is defined as an adverse event that starts on or after the start of study medication.
Time frame: First dose to end of treatment period
Number of Subjects Reporting at Least One Serious Treatment Emergent Adverse Event
A Serious Treatment Emergent Adverse Event is defined as any untoward medical occurrence at any dose of IV APAP that; * results in death * is life-threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event
Time frame: First dose to 30 days after last dose
Subject's (Parent/Guardian) Global Evaluation of Study Treatment
Subject's (parent/guardian) was asked to evaluate the overall study treatment using a 4-point categorical evaluation scale (0= poor, 1= fair, 2=good, 3= excellent).
Time frame: Day 0 to Day 5, Day 7 or Early Termination from study
Physician's Global Assessment of Study Treatment
Physicians were asked to evaluate the overall study treatment using a 4-point categorical evaluation scale (0= poor, 1= fair,2=good, 3= excellent).
Time frame: End of study or Early Termination
Multi-center study conducted in the United States from 19 Mar 2008 - 24Dec 2008
| Milestone | Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h | Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h | Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h | Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h | Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h | Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h | Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h | Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h |
|---|---|---|---|---|---|---|---|---|
| Started | 1 | 3 | 7 | 33 | 9 | 42 | 1 | 4 |
| Completed | 1 | 1 | 5 | 25 | 6 | 30 | 0 | 4 |
| Not completed | 0 | 2 | 2 | 8 | 3 | 12 | 1 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Early discharge from hospital | 0 | 0 | 2 | 5 | 0 | 10 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Dose limiting toxicity | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
Subject's (parent/guardian) was asked to evaluate the overall study treatment using a 4-point categorical evaluation scale (0= poor, 1= fair, 2=good, 3= excellent).
| participants | Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h | Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h | Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h | Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h | Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h | Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h | Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h | Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h |
|---|---|---|---|---|---|---|---|---|
| Poor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fair | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Good | 0 | 3 | 1 | 11 | 3 | 17 | 0 | 1 |
| Excellent | 1 | 0 | 6 | 17 | 5 | 23 | 1 | 2 |
| Missing | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 1 |
A TEAE is defined as an adverse event that starts on or after the start of study medication.
| Subjects | Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h | Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h | Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h | Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h | Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h | Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h | Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h | Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects Reporting at Least One Treatment Emergent Adverse Event (TEAE) | 1 | 1 | 5 | 25 | 9 | 35 | 0 | 2 |
Physicians were asked to evaluate the overall study treatment using a 4-point categorical evaluation scale (0= poor, 1= fair,2=good, 3= excellent).
| participants | Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h | Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h | Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h | Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h | Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h | Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h | Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h | Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h |
|---|---|---|---|---|---|---|---|---|
| Poor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fair | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Good | 0 | 2 | 1 | 15 | 4 | 16 | 0 | 1 |
| Excellent | 1 | 1 | 6 | 13 | 5 | 25 | 1 | 2 |
| Missing | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 1 |
A Serious Treatment Emergent Adverse Event is defined as any untoward medical occurrence at any dose of IV APAP that; * results in death * is life-threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event
| Subjects | Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h | Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h | Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h | Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h | Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h | Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h | Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h | Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects Reporting at Least One Serious Treatment Emergent Adverse Event | 1 | 1 | 0 | 13 | 2 | 3 | 0 | 1 |
Collected over Non-serious treatment emergent adverse events (TEAEs) were collected from the initiation of treatment with study medication to the end of the patient's treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h | — | 1/1 (100%) | 1/1 (100%) |
| Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h | — | 1/3 (33.3%) | 1/3 (33.3%) |
| Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h | — | 0/7 (0%) | 5/7 (71.4%) |
| Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h | — | 13/33 (39.4%) | 24/33 (72.7%) |
| Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h | — | 2/9 (22.2%) | 9/9 (100%) |
| Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h | — | 3/42 (7.1%) | 33/42 (78.6%) |
| Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h | — | 0/1 (0%) | 0/1 (0%) |
| Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h | — | 1/4 (25%) | 2/4 (50%) |
| Event | Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h | Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h | Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h | Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h | Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h | Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h | Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h | Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h |
|---|---|---|---|---|---|---|---|---|
| Congenital MegacolonCongenital, familial and genetic disorders | 1/1 | 0/3 | 0/7 | 0/33 | 0/9 | 0/42 | 0/1 | 0/4 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/1 | 1/3 | 0/7 | 2/33 | 0/9 | 0/42 | 0/1 | 0/4 |
| Obstructive airways disorderRespiratory, thoracic and mediastinal disorders | 0/1 | 0/3 | 0/7 | 1/33 | 0/9 | 0/42 | 0/1 | 1/4 |
| HeadacheNervous system disorders | 0/1 | 0/3 | 0/7 | 0/33 | 1/9 | 0/42 | 0/1 | 0/4 |
| HepatotoxicityHepatobiliary disorders | 0/1 | 0/3 | 0/7 | 0/33 | 1/9 | 0/42 | 0/1 | 0/4 |
| ChylothoraxRespiratory, thoracic and mediastinal disorders | 0/1 | 0/3 | 0/7 | 2/33 | 0/9 | 0/42 | 0/1 | 0/4 |
| Hepatic enzyme increasedInvestigations | 0/1 | 0/3 | 0/7 | 2/33 | 0/9 | 1/42 | 0/1 | 0/4 |
| Wound InfectionInfections and infestations | 0/1 | 0/3 | 0/7 | 2/33 | 0/9 | 0/42 | 0/1 | 0/4 |
| Abdominal abscessInfections and infestations | 0/1 | 0/3 | 0/7 | 1/33 | 0/9 | 0/42 | 0/1 | 0/4 |
| Diaphragmatic disorderRespiratory, thoracic and mediastinal disorders | 0/1 | 0/3 | 0/7 | 1/33 | 0/9 | 0/42 | 0/1 | 0/4 |
| Event | Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h | Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h | Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h | Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h | Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h | Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h | Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h | Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h |
|---|---|---|---|---|---|---|---|---|
| Skin irritationSkin and subcutaneous tissue disorders | 1/1 | 0/3 | 0/7 | 0/33 | 0/9 | 0/42 | 0/1 | 0/4 |
| NauseaGastrointestinal disorders | 0/1 | 0/3 | 3/7 | 6/33 | 5/9 | 17/42 | 0/1 | 0/4 |
| AgitationPsychiatric disorders | 0/1 | 0/3 | 0/7 | 3/33 | 0/9 | 0/42 | 0/1 | 2/4 |
| WheezingRespiratory, thoracic and mediastinal disorders | 0/1 | 0/3 | 0/7 | 1/33 | 0/9 | 0/42 | 0/1 | 2/4 |
| PruritisSkin and subcutaneous tissue disorders | 0/1 | 0/3 | 2/7 | 5/33 | 4/9 | 4/42 | 0/1 | 0/4 |
| VomitingGastrointestinal disorders | 0/1 | 0/3 | 2/7 | 7/33 | 4/9 | 10/42 | 0/1 | 1/4 |
| AnemiaBlood and lymphatic system disorders | 0/1 | 1/3 | 1/7 | 2/33 | 0/9 | 2/42 | 0/1 | 0/4 |
| ConstipationGastrointestinal disorders | 0/1 | 0/3 | 0/7 | 11/33 | 2/9 | 10/42 | 0/1 | 1/4 |
| HeadacheNervous system disorders | 0/1 | 0/3 | 0/7 | 1/33 | 3/9 | 4/42 | 0/1 | 0/4 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/1 | 1/3 | 0/7 | 0/33 | 0/9 | 1/42 | 0/1 | 0/4 |
| Age, Categorical(Participants) | Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h | Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h | Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h | Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h | Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h | Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h | Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h | Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 1 | 3 | 7 | 33 | 9 | 42 | 1 | 4 | 100 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Neonates (<= 28 Days Old): IV APAP 10 - 15 mg/kg q8h | Infants (29 Days to 1 Year Old): IV APAP 10 - 15 mg/kg q6h | Children (2 to < 12 Years Old): IV APAP 6.7 - 12.5 mg/kg q4h | Children (2 to < 12 Years Old): IV APAP 10 - 15 mg/kg q6h | Adolescents (12 to <= 16 Years): IV APAP 6.7 - 12.5 mg/kg q4h | Adolescents (12 to <= 16 Years Old): IV APAP 10 - 15 mg/kg q6h | Infants (12 to < 24 Months): IV APAP 6.7 - 12.5 mg/kg q4h | Infants (12 to < 24 Months): IV APAP 10 - 15 mg/kg q6h | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 2 | 5 | 17 | 6 | 29 | 0 | 3 | 62 |
| Male | 1 | 1 | 2 | 16 | 3 | 13 | 1 | 1 | 38 |
The record gives a start of Jan 2008, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 2 years 1 month after primary completion. A results delay was requested in Apr 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen